• 2012 G3 Therapeutics ​

​

• 09/25/2013 Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics

​

• 11/14/2013 Global Genomics Group and Metabolon to Collaborate
   

• 02/26/2014 Global Genomics Group (G3) and Caprion to Partner on Global Study to Identify Cardiovascular Disease Biomarkers and Drug Targets​

​

• 11/2014 Precision phenotyping, panomics, and system-level bioinformatics to delineate complex biologies of atherosclerosis: rationale and design of the "Genetic Loci and the Burden of Atherosclerotic Lesions" study​

​

• 2014 GLOBAL Clinical Study (GLOBAL)(WHICH DATE TO USE?)

• ​​​

• 01/05/2016 Global Genomics Group (G3) Partners with Sanofi to Identify New Signaling Pathways in Atherosclerotic Cardiovascular Diseases​

​

• ​03/17/2017 Global Genomics Group Announces Breakthrough Diagnostic Blood Test for Plaque Detection in the Heart​

​

• 2019 JV with Juvenescence ​

• (WHICH DATE TO USE?)

​

• 06/01/2020 G3 Therapeutics and Juvenescence Limited Announce the Formation of Juvenomics, a Visionary Company Founded on Applying Deep Molecular Profiling and Deep Learning to Tackle Aging​​

​

• 12/22/2020 Valo Announces Exclusive Partnership with G3 the World's Largest and Detailed Cardio-Metabolic Datasets

​

• 03/16/2022 Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications​​

​

• 2022 B4X Therapeutics

​​​

• 01/12/2023 Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide​

​

• 01/03/2023 Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis development​​

​

• 01/20/2023 Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide​

​

• 2023 PUER ​​​

​

• 01/04/2024 Little (a), Big Risk: G3 Therapeutics Sets Out to Unravel Lp(a)-Driven Cardiovascular Disease (Lipoprotein(a)-Driven Cardiovascular Disease)